Contract

ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE

  • Business Energy and Industrial Strategy

F03: Contract award notice

Notice identifier: 2021/S 000-002970

Procurement identifier (OCID): ocds-h6vhtk-029301

Published 12 February 2021, 5:45pm



Section one: Contracting authority

one.1) Name and addresses

Business Energy and Industrial Strategy

1 Victoria Street

London

SW1H0ET

Email

VTFContracts@beis.gov.uk

Country

United Kingdom

NUTS code

UK - UNITED KINGDOM

Internet address(es)

Main address

https://www.gov.uk/government/organisations/department-for-business-energy-and-industrial-strategy

one.4) Type of the contracting authority

Ministry or any other national or federal authority

one.5) Main activity

General public services


Section two: Object

two.1) Scope of the procurement

two.1.1) Title

ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE

Reference number

4846/01/2021

two.1.2) Main CPV code

  • 33651600 - Vaccines

two.1.3) Type of contract

Supplies

two.1.4) Short description

Procurement of Janssen's vaccine candidate Ad26.COV2-S.

two.1.6) Information about lots

This contract is divided into lots: No

two.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £1

two.2) Description

two.2.3) Place of performance

NUTS codes
  • BE - BELGIUM

two.2.4) Description of the procurement

This contract has been procured using the negotiated procedure without prior publication under regulation 32 of the Public Contracts Regulations 2015 on the basis that the award of the contract to Janssen is strictly necessary for unforeseeable reasons of extreme urgency; i.e. the urgent requirement to secure priority access to a viable vaccine to end the Covid-19 pandemic (Regulation 32(2)(c)).

two.2.5) Award criteria

Price

two.2.11) Information about options

Options: No

two.2.14) Additional information

Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vaccine vendors and (iii) impact fair competition between vaccine vendors.


Section four. Procedure

four.1) Description

four.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

  • Extreme urgency brought about by events unforeseeable for the contracting authority

Explanation:

The award of the contract to Janssen is strictly necessary for unforeseeable reasons of extreme urgency; i.e. the urgent requirement to find a viable vaccine to end the Covid 19 pandemic (Regulation 32(2)(c)).

four.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes


Section five. Award of contract

Contract No

4846/01/2021

Title

ADVANCE PURCHASE AGREEMENT FOR SARS-CoV-2/COVID-19 VACCINE

A contract/lot is awarded: Yes

five.2) Award of contract

five.2.1) Date of conclusion of the contract

15 January 2021

five.2.2) Information about tenders

Number of tenders received: 1

The contract has been awarded to a group of economic operators: No

five.2.3) Name and address of the contractor

JANSSEN PHARMACEUTICA NV

30 Turnhoutseweg

Beerse

B-2340

Country

Belgium

NUTS code
  • BE - BELGIUM
The contractor is an SME

No

five.2.4) Information on value of contract/lot (excluding VAT)

Initial estimated total value of the contract/lot: £1

Total value of the contract/lot: £1


Section six. Complementary information

six.4) Procedures for review

six.4.1) Review body

Department of Business, Energy and Industrial Strategy

1 Victoria Street

London

SW1H 0ET

Country

United Kingdom